IRIDEX Corp. (IRIX) reported a second-quarter net loss of $1.3 million, or 7 cents per share, widening from a $1.0 million loss, or 6 cents per share, in the same period last year. Revenue decreased 7% to $12.6 million, missing Wall Street's estimate of $14.13 million by $1.53 million.
Uttaget var $4,3 millioner, med en brutto margin på 34,2%, medan driftskostnadene sank med 5% til $5,3 millioner. Justert EBITDA blev negativt med en tap på $400 000, jämfört med en vinst på $21 000 ett år tidigare. Mjuk- och kontantlikvider steg med $100 000 till $4,7 millioner under kvartalet.
Firma’s glaucoma business, driven by the Cyclo G6 platform, increased 19% year-over-year to $3.9 million, with probe volume rising 35% to 17,700 units. However, system placements declined to 18 from 35 in the prior-year period. Retina revenue dropped 19% to $6.5 million amid operational challenges and market dynamics.
Chief Executive Officer Patrick Mercer highlighted the company's positive operating cash flow as an "important inflection point," citing two years of cost restructuring and improved working capital. He noted the steady adoption of the Cyclo G6 platform across regions, but acknowledged challenges in the retina segment.
Chief Financial Officer Romeo Dizon descrie l'amélioration des flux de trésorerie comme un « indiquant significatif » de discipline financière, ajoutant que la création de stocks de sécurité pour les distributeurs a précédé le déménagement du siège social. IRIDEX a reconfirmé son prévision de revenus sur l'ensemble de l'année 2026 s'échelonnant entre 51 millions de dollars et 53 millions de dollars, excluant les revenus dans la région Moyen-Orient en raison du conflit régional, impliquant une croissance pro forma de 1 % à 5 % par rapport à 2025.
الأسهم ارتفعت بنسبة 5.69٪ لتبلغ 0.93 دولار في التداول العادي، ولكن انخفضت بنسبة 4.31٪ إلى 0.89 دولار في النشاط بعد ساعات. ارتدّت الأسهم بين 0.804 دولار و 1.648 دولار خلال الـ 52 أسبوعًا الماضية.
